Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections

References

• Esposito S, Noviello S, Leone S. Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis. 2016 Apr;29(2):109–115. PubMed PMID: 26779772.
   PubMed Web of Science ®Google Scholar
• Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008 Mar;51(3):291–298. PubMed PMID: 18222564.
   PubMed Web of Science ®Google Scholar
• Esposito S, Noviello S, De Caro F, et al. New insights into classification, epidemiology and microbiology of SSTIs, including diabetic foot infections. Infez Med. 2018 Mar 1;26(1):3–14. PubMed PMID: 29525792.
   PubMedGoogle Scholar
• Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment Silver Spring MUDoHaHS, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2013 [cited 2019 Dec 12]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071185.pdf
   Google Scholar
• Esposito S, De Simone G, Pan A, et al. Epidemiology and microbiology of skin and soft tissue infections: preliminary results of a national registry. J Chemother. 2019 Feb;31(1):9–14. PubMed PMID: 30508410.
   PubMed Web of Science ®Google Scholar
• Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis. 2007 Jan;57(1):7–13. PubMed PMID: 17059876.
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006 Aug 17;355(7):666–674. PubMed PMID: 16914702.
   PubMed Web of Science ®Google Scholar
• Lopez Furst MJ, de Vedia L, Fernandez S, et al. Prospective multicenter study of community-associated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus in Buenos Aires, Argentina. PLoS One. 2013;8(11):e78303. PubMed PMID: 24324543; PubMed Central PMCID: PMCPMC3855813.
   PubMed Web of Science ®Google Scholar
• Suaya JA, Mera RM, Cassidy A, et al. Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009. BMC Infect Dis. 2014 June;2(14):296. PubMed PMID: 24889406; PubMed Central PMCID: PMCPMC4060579.
   PubMed Web of Science ®Google Scholar
• DeLeo FR, Otto M, Kreiswirth BN, et al. Community-associated meticillin-resistant Staphylococcus aureus. Lancet. 2010 May 1;375(9725):1557–1568. PubMed PMID: 20206987; PubMed Central PMCID: PMCPMC3511788.
   PubMed Web of Science ®Google Scholar
• Esposito S, De Simone G. Update on the main MDR pathogens: prevalence and treatment options. Infez Med. 2017 Dec 1;;25(4):301–310. PubMed PMID: 29286008.
   PubMedGoogle Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014 July 15;59(2):e10–52. PubMed PMID: 24973422.
   PubMed Web of Science ®Google Scholar
• Hall RGN, Thatcher M, Wei W, et al. Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options). Expert Rev Clin Pharmacol. 2017 May;10(5):493–508. PubMed PMID: 28293964.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis. 2005 June 15;40(12):1785–1791. PubMed PMID: 15909267.
   PubMed Web of Science ®Google Scholar
• Bowen AC, Lilliebridge RA, Tong SY, et al. Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole? J Clin Microbiol. 2012 Dec;50(12):4067–4072. PubMed PMID: 23052313; PubMed Central PMCID: PMCPMC3502963.
   PubMed Web of Science ®Google Scholar
• Payne KD, Das A, Ndiulor M, et al. Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options). Expert Rev Clin Pharmacol. 2018 Feb;11(2):139–149. PubMed PMID: 29186999.
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci. 2011 Dec;1241:48–70. PubMed PMID: 22191526.
   PubMed Web of Science ®Google Scholar
• Locke JB, Zurenko GE, Shaw KJ, et al. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis. 2014 Jan;58(Suppl 1):S35–42. PubMed PMID: 24343830.
   PubMed Web of Science ®Google Scholar
• Locke JB, Finn J, Hilgers M, et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother. 2010 Dec;54(12):5337–5343. PubMed PMID: 20837751; PubMed Central PMCID: PMCPMC2981267.
   PubMed Web of Science ®Google Scholar
• Lemaire S, Van Bambeke F, Appelbaum PC, et al. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother. 2009 Nov;64(5):1035–1043. PubMed PMID: 19759040.
   PubMed Web of Science ®Google Scholar
• Flanagan S, Bartizal K, Minassian SL, et al. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother. 2013 July;57(7):3060–3066. PubMed PMID: 23612197; PubMed Central PMCID: PMCPMC3697335.
   PubMed Web of Science ®Google Scholar
• Flanagan S, Fang E, Munoz KA, et al. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy. 2014 Sep;34(9):891–900. PubMed PMID: 24989138; PubMed Central PMCID: PMCPMC4260119.
   PubMed Web of Science ®Google Scholar
• Ferrandez O, Urbina O, Grau S. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections. Drug Des Devel Ther. 2017;11:65–82. PubMed PMID: 28053508; PubMed Central PMCID: PMCPMC5191846.
   PubMed Web of Science ®Google Scholar
• Flanagan SD, Bien PA, Munoz KA, et al. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy. 2014 Mar;34(3):240–250. PubMed PMID: 23926058; PubMed Central PMCID: PMCPMC4238735.
   PubMed Web of Science ®Google Scholar
• Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012 May;56(5):2627–2634. PubMed PMID: 22330925; PubMed Central PMCID: PMCPMC3346604.
   PubMed Web of Science ®Google Scholar
• Ong V, Flanagan S, Fang E, et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos. 2014 Aug;42(8):1275–1284. PubMed PMID: 24875463.
   PubMed Web of Science ®Google Scholar
• Sahre M, Sabarinath S, Grant M, et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents. 2012 July;40(1):51–54. PubMed PMID: 22584101; PubMed Central PMCID: PMCPMC3789129.
   PubMed Web of Science ®Google Scholar
• Stainton SM, Monogue ML, Baummer-Carr A, et al. Comparative assessment of tedizolid pharmacokinetics and tissue penetration between diabetic patients with wound infections and healthy volunteers via in vivo microdialysis. Antimicrob Agents Chemother. 2018 Jan;62(1). DOI:10.1128/AAC.01880-17. PubMed PMID: 29109162; PubMed Central PMCID: PMCPMC5740339.
   Web of Science ®Google Scholar
• Flanagan S, Passarell J, Lu Q, et al. Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrob Agents Chemother. 2014 Nov;58(11):6462–6470. PubMed PMID: 25136028; PubMed Central PMCID: PMCPMC4249359.
   PubMed Web of Science ®Google Scholar
• Pai MP. Pharmacokinetics of tedizolid in morbidly obese and covariate-matched nonobese adults. Antimicrob Agents Chemother. 2016 Aug;60(8):4585–4589. PubMed PMID: 27185808; PubMed Central PMCID: PMCPMC4958168.
   PubMed Web of Science ®Google Scholar
• Bradley JS, Flanagan SD, Arrieta AC, et al. Pharmacokinetics, safety and tolerability of single oral or intravenous administration of 200 mg tedizolid phosphate in adolescents. Pediatr Infect Dis J. 2016 June;35(6):628–633. PubMed PMID: 26910588.
   PubMed Web of Science ®Google Scholar
• Flanagan SD, Minassian SL, Prokocimer P. Pharmacokinetics, safety, and tolerability of tedizolid phosphate in elderly subjects. Clin Pharmacol Drug Dev. 2018 Sept;7(7):788–794. PubMed PMID: 29319932.
   PubMed Web of Science ®Google Scholar
• Flanagan S, Minassian SL, Morris D, et al. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother. 2014 Nov;58(11):6471–6476. PubMed PMID: 25136024; PubMed Central PMCID: PMCPMC4249404.
   PubMed Web of Science ®Google Scholar
• Louie A, Liu W, Kulawy R, et al. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother. 2011 Jul;55(7):3453–3460. PubMed PMID: 21502615; PubMed Central PMCID: PMCPMC3122459.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Liu W, Kulawy R, et al. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother. 2011 Nov;55(11):5300–5305. PubMed PMID: 21911576; PubMed Central PMCID: PMCPMC3195040.
   PubMed Web of Science ®Google Scholar
• Abdelraouf K, Nicolau DP. Comparative in vivo efficacies of tedizolid in neutropenic versus immunocompetent murine Streptococcus pneumoniae lung infection models. Antimicrob Agents Chemother. 2017 Jan;61(1). DOI:10.1128/AAC.01957-16. PubMed PMID: 27799200; PubMed Central PMCID: PMCPMC5192146.
   PubMed Web of Science ®Google Scholar
• Xiao J, Gill C, Liang L, et al. Use of translational pharmacokinetic/pharmacodynamic infection models to understand the impact of neutropenia on the efficacy of tedizolid phosphate. Antimicrob Agents Chemother. 2019 Jan;63(1). DOI:10.1128/AAC.00822-18. PubMed PMID: 30373794; PubMed Central PMCID: PMCPMC6325206.
   Web of Science ®Google Scholar
• Lodise TP, Drusano GL. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate. Clin Infect Dis. 2014 Jan;58(Suppl 1):S28–34. PubMed PMID: 24343829.
   PubMed Web of Science ®Google Scholar
• Werth BJ. Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis. J Antimicrob Chemother. 2017 May 1;72(5):1410–1414. PubMed PMID: 28158617; PubMed Central PMCID: PMCPMC5890700.
   PubMed Web of Science ®Google Scholar
• Smith JR, Yim J, Rice S, et al. Combination of tedizolid and daptomycin against methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother. 2018 May;62(5). DOI:10.1128/AAC.00101-18. PubMed PMID: 29530843; PubMed Central PMCID: PMCPMC5923122.
   Web of Science ®Google Scholar
• Katahira EJ, Davidson SM, Stevens DL, et al. Subinhibitory concentrations of tedizolid potently inhibit extracellular toxin production by methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Med Microbiol. 2019 Feb;68(2):255–262. PubMed PMID: 30556803; PubMed Central PMCID: PMCPMC6557147.
   PubMed Web of Science ®Google Scholar
• Le VT, Le HN, Pinheiro MG, et al. Effects of tedizolid phosphate on survival outcomes and suppression of production of staphylococcal toxins in a rabbit model of methicillin-resistant staphylococcus aureus necrotizing pneumonia. Antimicrob Agents Chemother. 2017 Apr;61(4). DOI:10.1128/AAC.02734-16. PubMed PMID: 28137816; PubMed Central PMCID: PMCPMC5365717.
   Web of Science ®Google Scholar
• Delpech P, AL M, Jones B, et al. An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections. Diagn Microbiol Infect Dis. 2018 May;91(1):93–97. PubMed PMID: 29452993..
   PubMed Web of Science ®Google Scholar
• Park KH, Greenwood-Quaintance KE, Schuetz AN, et al. Activity of tedizolid in methicillin-resistant Staphylococcus epidermidis experimental foreign body-associated osteomyelitis. Antimicrob Agents Chemother. 2017 Feb;61(2). DOI:10.1128/AAC.01644-16. PubMed PMID: 27855069; PubMed Central PMCID: PMCPMC5278734.
   Web of Science ®Google Scholar
• Abad L, Tafani V, Tasse J, et al. Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting. J Antimicrob Chemother. 2019 Mar 1;74(3):625–632. PubMed PMID: 30517641.
   PubMed Web of Science ®Google Scholar
• Kaku N, Morinaga Y, Takeda K, et al. Antimicrobial and immunomodulatory effects of tedizolid against methicillin-resistant Staphylococcus aureus in a murine model of hematogenous pulmonary infection. Int J Med Microbiol. 2016 Sept;306(6):421–428. PubMed PMID: 27259840.
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother. 2008 Dec;52(12):4442–4447. PubMed PMID: 18838596; PubMed Central PMCID: PMCPMC2592863.
   PubMed Web of Science ®Google Scholar
• Bensaci M, Sahm D. Surveillance of tedizolid activity and resistance: in vitro susceptibility of gram-positive pathogens collected over 5 years from the United States and Europe. Diagn Microbiol Infect Dis. 2017 Feb;87(2):133–138. PubMed PMID: 27866673.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Hackel MA, Bouchillon SK, et al. In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016. Diagn Microbiol Infect Dis. 2017 Oct;89(2):151–157. PubMed PMID: 28793964.
   PubMed Web of Science ®Google Scholar
• Bai B, Hu K, Li H, et al. Effect of tedizolid on clinical Enterococcus isolates: in vitro activity, distribution of virulence factor, resistance genes and multilocus sequence typing. FEMS Microbiol Lett. 2018 Feb 1;365(3). DOI:10.1093/femsle/fnx284. PubMed PMID: 29390078.
   Web of Science ®Google Scholar
• Corey R, Moran G, Goering R, et al. Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials. Diagn Microbiol Infect Dis. 2019 July;94(3):277–286. PubMed PMID: 30940414.
   PubMed Web of Science ®Google Scholar
• Mikamo H, Takesue Y, Iwamoto Y, et al. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan – results of a randomised, multicentre phase 3 study. J Infect Chemother. 2018 June;24(6):434–442. PubMed PMID: 29530544.
   PubMed Web of Science ®Google Scholar
• Lv X, Alder J, Li L, et al. Efficacy and safety of tedizolid phosphate versus linezolid in a randomized phase 3 trial in patients with acute bacterial skin and skin structure infection. Antimicrob Agents Chemother. 2019 July;63(7). DOI:10.1128/AAC.02252-18. PubMed PMID: 30988146; PubMed Central PMCID: PMCPMC6591607.
   Web of Science ®Google Scholar
• Pfaller MA, Sader HS, Rhomberg PR, et al. In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother. 2017 Apr;61(4). DOI:10.1128/AAC.02609-16. PubMed PMID: 28167542; PubMed Central PMCID: PMCPMC5365668.
   Web of Science ®Google Scholar
• Pfaller MA, Sader HS, Rhomberg PR, et al. In vitro activity of tedizolid in comparison with other oral and intravenous agents against a collection of community-acquired methicillin-resistant Staphylococcus aureus (2014–2015) in the United States. Microb Drug Resist. 2019 July/Aug;25(6):938–943. PubMed PMID: 30694735.
   PubMed Web of Science ®Google Scholar
• Yum JH, Choi SH, Yong D, et al. Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea. Antimicrob Agents Chemother. 2010 Dec;54(12):5381–5386. PubMed PMID: 20837761; PubMed Central PMCID: PMCPMC2981271.
   PubMed Web of Science ®Google Scholar
• Barber KE, Smith JR, Raut A, et al. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. J Antimicrob Chemother. 2016 Jan;71(1):152–155. PubMed PMID: 26476277.
   PubMed Web of Science ®Google Scholar
• Thomson KS, Goering RV. Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins. Antimicrob Agents Chemother. 2013 Jun;57(6):2892–2895. PubMed PMID: 23571550; PubMed Central PMCID: PMCPMC3716181.
   PubMed Web of Science ®Google Scholar
• Lee Y, Hong SK, Choi S, et al. In vitro activity of tedizolid against gram-positive bacteria in patients with skin and skin structure infections and hospital-acquired pneumonia: a Korean multicenter study. Ann Lab Med. 2015 Sept;35(5):523–530. PubMed PMID: 26206690; PubMed Central PMCID: PMCPMC4510506.
   PubMed Web of Science ®Google Scholar
• Brown SD, Traczewski MM. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother. 2010 May;54(5):2063–2069. PubMed PMID: 20231392; PubMed Central PMCID: PMCPMC2863606.
   PubMed Web of Science ®Google Scholar
• Betts JW, Abdul Momin HF, Phee LM, et al. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides. J Med Microbiol. 2018 Feb;67(2):265–271. PubMed PMID: 29300156.
   PubMed Web of Science ®Google Scholar
• Gu B, Kelesidis T, Tsiodras S, et al. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother. 2013 Jan;68(1):4–11. PubMed PMID: 22949625.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Avial I, Culebras E, Betriu C, et al. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother. 2012 Jan;67(1):167–169. PubMed PMID: 21954458.
   PubMed Web of Science ®Google Scholar
• Singh KV, Arias CA, Murray BE. Efficacy of tedizolid against enterococci and Staphylococci, including cfr (+) strains, in a mouse peritonitis model. Antimicrob Agents Chemother. 2019 Apr;63(4). DOI:10.1128/AAC.02627-18. PubMed PMID: 30670435; PubMed Central PMCID: PMCPMC6437489.
   Web of Science ®Google Scholar
• Chen KH, Huang YT, Liao CH, et al. In vitro activities of tedizolid and linezolid against gram-positive cocci associated with acute bacterial skin and skin structure infections and pneumonia. Antimicrob Agents Chemother. 2015 Oct;59(10):6262–6265. PubMed PMID: 26248355; PubMed Central PMCID: PMCPMC4576035.
   PubMed Web of Science ®Google Scholar
• CLSI (Clinical and Laboratory Standards Institute). Performance standards for antimicrobial susceptibility testing. 29th ed. Wayne (PA):CLSI;2019. CLSI supplement M100S.
   Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0. [cited 2019 Nov 6]. Available from: eucast.org
   Google Scholar
• Goldstein EJ, Citron DM, Tyrrell KL, et al. The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems. Anaerobe. 2017 Feb;43:1–3. PubMed PMID: 27713022.
   PubMed Web of Science ®Google Scholar
• Binyamin D, Nitzan O, Azrad M, et al. In vitro activity of tedizolid, dalbavancin, and ceftobiprole against clostridium difficile. Front Microbiol. 2018;9:1256. PubMed PMID: 29942295; PubMed Central PMCID: PMCPMC6004428.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Love R, Adam H, et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs. 2015 Feb;75(3):253–270. PubMed PMID: 25673021.
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Wallace RJ Jr. In vitro susceptibility testing of tedizolid against isolates of nocardia. Antimicrob Agents Chemother. 2017 Dec;61(12). DOI:10.1128/AAC.01537-17. PubMed PMID: 28923878; PubMed Central PMCID: PMCPMC5700301.
   Web of Science ®Google Scholar
• Vera-Cabrera L, Gonzalez E, Rendon A, et al. In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob Agents Chemother. 2006 Sep;50(9):3170–3172. PubMed PMID: 16940121; PubMed Central PMCID: PMCPMC1563545.
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Wallace RJ Jr. In vitro susceptibility testing of tedizolid against nontuberculous mycobacteria. J Clin Microbiol. 2017 Jun;55(6):1747–1754. PubMed PMID: 28330892; PubMed Central PMCID: PMCPMC5442531.
   PubMed Web of Science ®Google Scholar
• Ruth MM, Koeken V, Pennings LJ, et al. Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease? J Antimicrob Chemother. 2020 Mar 1;75(3):609–617. PubMed PMID: 31886864; PubMed Central PMCID: PMCPMC7021090.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Deshpande D, Nuermberger E, et al. The sterilizing effect of intermittent tedizolid for pulmonary tuberculosis. Clin Infect Dis. 2018 Nov 28;67(suppl_3):S336–S341. PubMed PMID: 30496463; PubMed Central PMCID: PMCPMC6260152.
   PubMed Web of Science ®Google Scholar
• Hasannejad-Bibalan M, Mojtahedi A, Biglari H, et al. Antibacterial activity of tedizolid, a novel oxazolidinone against methicillin-resistant staphylococcus aureus: a systematic review and meta-analysis. Microb Drug Resist. 2019 Nov;25(9):1330–1337. PubMed PMID: 31290721.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Mendes RE, Bensaci M. In vitro activity of tedizolid against clinical isolates of Staphylococcus lugdunensis and Staphylococcus haemolyticus from Europe and the United States. Diagn Microbiol Infect Dis. 2019 Jan;93(1):85–88. PubMed PMID: 30314652.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lv Y, Cai J, et al. A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin. J Antimicrob Chemother. 2015 Aug;70(8):2182–2190. PubMed PMID: 25977397.
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Castanheira M, Flamm RK, et al. Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program. J Antimicrob Chemother. 2018 Sep 1;73(9):2314–2322. PubMed PMID: 29878213.
   PubMed Web of Science ®Google Scholar
• Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2011 Feb;55(2):583–592. PubMed PMID: 21115795; PubMed Central PMCID: PMCPMC3028792.
   PubMed Web of Science ®Google Scholar
• Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013 Feb 13;309(6):559–569. PubMed PMID: 23403680.
   PubMed Web of Science ®Google Scholar
• Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014 Aug;14(8):696–705. PubMed PMID: 24909499.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Lodise TP, Corey GR, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015 Feb;59(2):864–871. PubMed PMID: 25421472; PubMed Central PMCID: PMCPMC4335893.
   PubMed Web of Science ®Google Scholar
• Moran GJ, De Anda C, Das AF, et al. Efficacy and safety of tedizolid and linezolid for the treatment of acute bacterial skin and skin structure infections in injection drug users: analysis of two clinical trials. Infect Dis Ther. 2018 Dec;7(4):509–522. PubMed PMID: 30242736; PubMed Central PMCID: PMCPMC6249184.
   PubMed Web of Science ®Google Scholar
• De Anda C, Anuskiewicz S, Prokocimer P, et al. Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: subgroup analysis of 2 randomized phase 3 trials. Medicine (Baltimore). 2017 Dec;96(52):e9163. PubMed PMID: 29384903; PubMed Central PMCID: PMCPMC6392685.
   PubMed Web of Science ®Google Scholar
• Ortiz-Covarrubias A, Fang E, Prokocimer PG, et al. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections. Braz J Infect Dis. 2016 Mar–Apr;20(2):184–192. PubMed PMID: 26859064.
   PubMed Web of Science ®Google Scholar
• Sandison T, De Anda C, Fang E, et al. Clinical response of tedizolid versus linezolid in acute bacterial skin and skin structure infections by severity measure using a pooled analysis from two phase 3 double-blind trials. Antimicrob Agents Chemother. 2017 May;61(5). DOI:10.1128/AAC.02687-16. PubMed PMID: 28264845; PubMed Central PMCID: PMCPMC5404528.
   Web of Science ®Google Scholar
• Lan SH, Lin WT, Chang SP, et al. Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis. Antibiotics (Basel). 2019 Sept 4;8(3). DOI:10.3390/antibiotics8030137. PubMed PMID: 31487837; PubMed Central PMCID: PMCPMC6784229.
   Web of Science ®Google Scholar
• McCool R, Gould IM, Eales J, et al. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA. BMC Infect Dis. 2017 Jan 7;17(1):39. PubMed PMID: 28061827; PubMed Central PMCID: PMCPMC5219662.
   PubMed Web of Science ®Google Scholar
• Shlyapnikov S, Jauregui A, Khachatryan NN, et al. Real-life evidence for tedizolid phosphate in the treatment of cellulitis and wound infections: a case series. Infect Dis Ther. 2018 Sep;7(3):387–399. PubMed PMID: 30003513; PubMed Central PMCID: PMCPMC6098749.
   PubMed Web of Science ®Google Scholar
• Kullar R, Puzniak LA, Swindle JP, et al. Retrospective real-world evaluation of outcomes in patients with skin and soft structure infections treated with tedizolid in an outpatient setting. Infect Dis Ther. 2020 Mar;9(1):107–117. PubMed PMID: 31974828; PubMed Central PMCID: PMCPMC7054470.
   PubMed Web of Science ®Google Scholar
• Mensa Vendrell M, Tasias Pitarch M, Salavert Lleti M, et al. Safety and tolerability of more than 6 days of tedizolid treatment. Antimicrob Agents Chemother. 2020 Apr 20. DOI:10.1128/AAC.00356-20. PubMed PMID: 32312777.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Fang E, Minassian SL, et al. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Antimicrob Agents Chemother. 2014 Dec;58(12):7198–7204. PubMed PMID: 25246392; PubMed Central PMCID: PMCPMC4249542.
   PubMed Web of Science ®Google Scholar
• Lee EY, Caffrey AR. Thrombocytopenia with Tedizolid and Linezolid. Antimicrob Agents Chemother. 2018 Jan;62(1). DOI:10.1128/AAC.01453-17. PubMed PMID: 29038274; PubMed Central PMCID: PMCPMC5740346.
   Web of Science ®Google Scholar
• Schlosser MJ, Hosako H, Radovsky A, et al. Lack of neuropathological changes in rats administered tedizolid phosphate for nine months. Antimicrob Agents Chemother. 2015 Jan;59(1):475–481. PubMed PMID: 25385101; PubMed Central PMCID: PMCPMC4291389.
   PubMed Web of Science ®Google Scholar
• Hardalo C, Lodise TP, Bidell M. et al. Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections. Expert Opin Drug Saf. 2018 Apr;17(4):359–367. PubMed PMID: 29528251.
   PubMed Web of Science ®Google Scholar
• Flanagan S, McKee EE, Das D, et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother. 2015 Jan;59(1):178–185. PubMed PMID: 25331703; PubMed Central PMCID: PMCPMC4291347.
   PubMed Web of Science ®Google Scholar
• Milosevic TV, Payen VL, Sonveaux P, et al. Mitochondrial alterations (inhibition of mitochondrial protein expression, oxidative metabolism, and ultrastructure) induced by linezolid and tedizolid at clinically relevant concentrations in cultured human HL-60 promyelocytes and THP-1 monocytes. Antimicrob Agents Chemother. 2018 Mar;62(3). DOI:10.1128/AAC.01599-17. PubMed PMID: 29263063; PubMed Central PMCID: PMCPMC5826137.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Bidell MR, Flanagan SD, et al. Characterization of the haematological profile of 21 days of tedizolid in healthy subjects. J Antimicrob Chemother. 2016 Sep;71(9):2553–2558. PubMed PMID: 27317442.
   PubMed Web of Science ®Google Scholar
• Fang E, Munoz KA, Prokocimer P. Characterization of neurologic and ophthalmologic safety of oral administration of tedizolid for up to 21 days in healthy volunteers. Am J Ther. 2017 Mar/Apr;24(2):e227–e233. PubMed PMID: 27941424.
   PubMed Web of Science ®Google Scholar
• Yuste JR, Berto J, Del Pozo JL, et al. Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity. J Antimicrob Chemother. 2017 Feb;72(2):625–628. PubMed PMID: 27999019.
   PubMed Web of Science ®Google Scholar
• Gimenez-Arufe V, Gutierrez-Urbon JM, Blanco-Aparicio M, et al. Pulmonary nocardiosis treated with tedizolid. Farm Hosp. 2019 Nov 1;43(6):208–210. PubMed PMID: 31705645.
   PubMed Web of Science ®Google Scholar
• Martínez Álvarez RM, Navarro Pardo I, Moreno García E, et al. Long-term safety of tedizolid in a patient with spondilodiscitis after switch from linezolid due to toxicity. Infect Dis Clin Pract. 2018;26(6). DOI:10.1097/IPC.0000000000000623
   Web of Science ®Google Scholar
• Ferry T, Batailler C, Conrad A, et al. Correction of linezolid-induced myelotoxicity after switch to tedizolid in a patient requiring suppressive antimicrobial therapy for multidrug-resistant Staphylococcus epidermidis prosthetic-joint infection. Open Forum Infect Dis. 2018 Oct;5(10):ofy246. PubMed PMID: 30370314; PubMed Central PMCID: PMCPMC6198638.
   PubMed Web of Science ®Google Scholar
• Nigo M, Luce AM, Arias CA. Long-term use of tedizolid as suppressive therapy for recurrent methicillin-resistant staphylococcus aureus graft infection. Clin Infect Dis. 2018 Jun 1;66(12):1975–1976. PubMed PMID: 29370350; PubMed Central PMCID: PMCPMC6248592.
   PubMed Web of Science ®Google Scholar
• Yuste JR, Serrano-Alonso M, Carmona-Torre F, et al. Efficacy and safety of long-term use of tedizolid after liver transplantation in an adolescent with pulmonary tuberculosis. J Antimicrob Chemother. 2019 Sep 1;74(9):2817–2819. PubMed PMID: 31106345.
   PubMed Web of Science ®Google Scholar
• Flanagan S, Minassian SL, Prokocimer P. Pharmacokinetics of tedizolid and pseudoephedrine administered alone or in combination in healthy volunteers. J Clin Med. 2018 Jun 14;7(6):150. PubMed PMID: 29899212; PubMed Central PMCID: PMCPMC6025247.
   PubMed Web of Science ®Google Scholar
• Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019 Jan 31;380(5):415–424. PubMed PMID: 30152252.
   PubMed Web of Science ®Google Scholar
• Chan LC, Basuino L, Dip EC, et al. Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2015;59(6):3252–3256. PubMed PMID: 25801564; PubMed Central PMCID: PMCPMC4432129.
   PubMed Web of Science ®Google Scholar
• Li HK, Rombach I, Zambellas R, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019 Jan 31;380(5):425–436. PubMed PMID: 30699315; PubMed Central PMCID: PMCPMC6522347.
   PubMed Web of Science ®Google Scholar
• Carvalhaes CG, Sader HS, Flamm RK, et al. Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014–17). J Antimicrob Chemother. 2019 July 1;74(7):1928–1933. PubMed PMID: 30932152.
   PubMed Web of Science ®Google Scholar
• Kidd JM, Abdelraouf K, Nicolau DP. Comparative efficacy of human-simulated epithelial lining fluid exposures of tedizolid, linezolid and vancomycin in neutropenic and immunocompetent murine models of staphylococcal pneumonia. J Antimicrob Chemother. 2019 Apr 1;74(4):970–977. PubMed PMID: 30561650.
   PubMed Web of Science ®Google Scholar
• Carvalhaes CG, Sader HS, Flamm RK, et al. Assessment of tedizolid in vitro activity and resistance mechanisms against a collection of enterococcus spp. causing invasive infections, including isolates requiring an optimized dosing strategy for daptomycin from U.S. and European Medical Centers, 2016 to 2018. Antimicrob Agents Chemother. 2020 Mar 24;64(4). DOI:10.1128/AAC.00175-20. PubMed PMID: 32015026; PubMed Central PMCID: PMCPMC7179311.
   Web of Science ®Google Scholar
• Abdelhady W, Mishra NN. comparative efficacies of linezolid vs. tedizolid in an experimental murine model of vancomycin-resistant enterococcal (VRE) bacteremia. Front Med (Lausanne). 2019;6:31. PubMed PMID: 30842947; PubMed Central PMCID: PMCPMC6391330.
   PubMed Web of Science ®Google Scholar
• Si S, Durkin MJ, Mercier MM, et al. Successful treatment of prosthetic joint infection due to vancomycin-resistant enterococci with tedizolid. Infect Dis Clin Pract (Baltim Md). 2017 Mar;25(2):105–107. PubMed PMID: 28428726; PubMed Central PMCID: PMCPMC5393450.
   PubMed Web of Science ®Google Scholar
• Gu L, Ma M, Zhang Y, et al. Comparative pharmacokinetics of tedizolid in rat plasma and cerebrospinal fluid. Regul Toxicol Pharmacol. 2019 Oct;107:104420. PubMed PMID: 31295511.
   PubMed Web of Science ®Google Scholar
• Matin A, Sharma S, Mathur P, et al. Myelosuppression-sparing treatment of central nervous system nocardiosis in a multiple myeloma patient utilizing a tedizolid-based regimen: a case report. Int J Antimicrob Agents. 2017 Apr;49(4):488–492. PubMed PMID: 28189735.
   PubMed Web of Science ®Google Scholar
• Khatchatourian L, Le Bourgeois A, Asseray N, et al. Correction of myelotoxicity after switch of linezolid to tedizolid for prolonged treatments. J Antimicrob Chemother. 2017 July 1;72(7):2135–2136. PubMed PMID: 28369418.
   PubMed Web of Science ®Google Scholar
• T Wa K, Markus A, Prevots DR, et al. Safety and tolerability of long term use of tedizolid for treatment of nontuberculous mycobacterial infections. Open Forum Infect Dis. 2016;3(Suppl 1):577.
   Google Scholar
• Kauf T, Xu P, Zivkovic M, et al. Cost implications of tedizolid use in acute bacterial skin and skin structure infection (Absssi) for hospitals and managed care organizations (Mcos). Value Health. 2015;18(3):A240.
   Web of Science ®Google Scholar
• Insinga R, Dalakaki E, Retsa MP, et al. Cost minimization analysis of tedizolid for the treatment of acute bacterial skin and skin sub-structure infections (Absssi) In Greece. Value Health. 2016;19(7):A417.
   Web of Science ®Google Scholar